qtr-three earnings per share $num-two.
sees fy adjusted earnings per share $num-one to $num - two from continuing operations.
qtr-three adjusted earnings per share $num-two.
qtr-three revenue rose num-two percent to $num-one billion.
sees year-six base business growth of num-one% to num-two% and covid testing down num-three% to up num-four%.
sees fy year-six diagnostics revenue up num-one% to num-two%.
sees fy year-six base business revenue growth of num-one% to num-two%.
compname reports num-one tests per day in september, with volumes declining week-over-week since that time.
sees fy adjusted tax rate about num-one% on an adjusted basis.
qtr-three adjusted earnings per share $num-one excluding items.
qtrly pcr testing volume averaged num-one per day, up from num-two per day in qtr-two of year-six.
qtrly base business for both diagnostics and drug development grew num-one% and num-two%.
qtr-three revenue rose num-two percent to $num-one billion.
qtr-three adjusted operating income was $num-one million, or num-two% of revenue.
qtrly organic revenue increased num-one% on a reported basis.
qtr-four operating income $num-one million versus refinitiv ibes estimate of $1.51 billion.
